Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients

This ongoing Phase 2 trial, sponsored by Memorial Sloan Kettering Cancer Center, investigates the efficacy of adding liver stereotactic ablative radiotherapy (L-SABR) to standard drug therapy, which includes anti-PD-(L)1 based immunotherapy and platinum-based chemotherapy, in patients with metastatic non-small cell lung cancer (NSCLC). The study aims to enroll 68 participants, with a primary endpoint of median progression-free survival. The trial began on December 9, 2022, and is expected to reach primary completion by December 9, 2026. Secondary endpoints and safety data will be evaluated, but specific results and statistical analyses are not yet available. Clinicians should consider the potential of L-SABR as an adjunctive treatment in metastatic NSCLC pending further data.

This study focuses on patients with non-small cell lung cancer, a common type of lung cancer that can spread to other parts of the body. Researchers are testing whether adding a special radiation treatment called liver stereotactic ablative radiotherapy (L-SABR) to standard drug therapies is more effective than using drugs alone. They want to see if this combination can help patients live longer without their cancer getting worse. If successful, this could offer new hope for patients with advanced lung cancer. However, it’s important to remember that this is still a study, and results may take time. Patients interested in participating should discuss it with their doctor to understand all options and potential risks.